The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients.
Aged
Aged, 80 and over
Cross-Sectional Studies
Delayed Diagnosis
Delivery of Health Care
/ standards
Female
Humans
Hypertension, Pulmonary
/ economics
Male
Middle Aged
Patient Satisfaction
/ statistics & numerical data
Qualitative Research
Quality of Life
/ psychology
Surveys and Questionnaires
United Kingdom
PHA-UK
Patient survey
Pulmonary hypertension
Real-life research
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
21 Mar 2019
21 Mar 2019
Historique:
received:
21
08
2018
accepted:
03
03
2019
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
9
8
2019
Statut:
epublish
Résumé
Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH). To better understand the impact of PH on patients and carers beyond clinical symptoms, the PHA-UK carried out a cross-sectional survey on the effect of PH on daily living, along with a follow-up survey assessing the financial impact of PH. This is a descriptive cross-sectional survey of adult patients with PH in the UK. A quantitative survey of four key topics (time to diagnosis, quality of life [QoL], financial impact and specialist treatment), was made available to PHA-UK members and patients on PH therapy, with a follow-up financial impact survey sent to those responders who agreed to be contacted further. Data collection was carried out in January and February 2017 for the main survey, and November and December 2017 for the financial impact survey. The main survey was completed by 567 individuals, and the financial follow-up survey by 171. Mean age of responders was 69 ± 17 years with 70% female. 60% of respondents said PH had a major impact on their QoL, with 45% reporting that treatment and management improves their QoL 'a lot'. The time between first experiencing symptoms and diagnosis was ≥1 year for 48% of patients, with 40% seeing 4+ doctors before diagnosis. 63% of patients reported financial worries. Patients in part-time and full-time work reported the greatest financial burden, with a 13 and 33% fall in monthly income respectively. Patients had positive experiences of treatment in specialist centres, with 62% rating their care 'excellent', and 92% saying they preferred travelling to a specialist centre rather than seeing a local non-specialist. This study reports the largest UK survey exploring issues affecting patients with PH. The study shows that despite the availability of new therapies, patients are still experiencing delays prior to diagnosis, and experiencing both emotional and financial impacts from the disease. By identifying the areas patients find most important in their treatment, this research can inform future care policies and long-term management to support patients living with PH and their families.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH). To better understand the impact of PH on patients and carers beyond clinical symptoms, the PHA-UK carried out a cross-sectional survey on the effect of PH on daily living, along with a follow-up survey assessing the financial impact of PH.
METHODS
METHODS
This is a descriptive cross-sectional survey of adult patients with PH in the UK. A quantitative survey of four key topics (time to diagnosis, quality of life [QoL], financial impact and specialist treatment), was made available to PHA-UK members and patients on PH therapy, with a follow-up financial impact survey sent to those responders who agreed to be contacted further. Data collection was carried out in January and February 2017 for the main survey, and November and December 2017 for the financial impact survey.
RESULTS
RESULTS
The main survey was completed by 567 individuals, and the financial follow-up survey by 171. Mean age of responders was 69 ± 17 years with 70% female. 60% of respondents said PH had a major impact on their QoL, with 45% reporting that treatment and management improves their QoL 'a lot'. The time between first experiencing symptoms and diagnosis was ≥1 year for 48% of patients, with 40% seeing 4+ doctors before diagnosis. 63% of patients reported financial worries. Patients in part-time and full-time work reported the greatest financial burden, with a 13 and 33% fall in monthly income respectively. Patients had positive experiences of treatment in specialist centres, with 62% rating their care 'excellent', and 92% saying they preferred travelling to a specialist centre rather than seeing a local non-specialist.
CONCLUSIONS
CONCLUSIONS
This study reports the largest UK survey exploring issues affecting patients with PH. The study shows that despite the availability of new therapies, patients are still experiencing delays prior to diagnosis, and experiencing both emotional and financial impacts from the disease. By identifying the areas patients find most important in their treatment, this research can inform future care policies and long-term management to support patients living with PH and their families.
Identifiants
pubmed: 30898139
doi: 10.1186/s12890-019-0827-5
pii: 10.1186/s12890-019-0827-5
pmc: PMC6429756
doi:
Types de publication
Journal Article
Langues
eng
Pagination
67Références
Psychosom Med. 2004 Nov-Dec;66(6):831-6
pubmed: 15564346
Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30
pubmed: 16456139
Chest. 2010 Feb;137(2):376-87
pubmed: 19837821
Psychosomatics. 2010 Jul-Aug;51(4):339-339.e8
pubmed: 20587763
Chest. 2011 Jul;140(1):19-26
pubmed: 21393391
Eur Respir J. 2012 Apr;39(4):945-55
pubmed: 21885399
Pulm Circ. 2013 Jan;3(1):89-94
pubmed: 23662179
Eur Respir Rev. 2013 Dec;22(130):535-42
pubmed: 24293469
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50
pubmed: 24355641
Nurs Health Sci. 2014 Dec;16(4):454-60
pubmed: 24730424
Lancet Respir Med. 2016 Apr;4(4):306-22
pubmed: 26975810
J Heart Lung Transplant. 2017 Sep;36(9):957-967
pubmed: 28302503
Medicine (Baltimore). 2017 Sep;96(39):e6783
pubmed: 28953608